Atrial Fibrillation Explained: Causes, Symptoms & Treatment

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making health decisions based on this content.

By SterlingMedicalCenter.org Editorial Team | Last verified: August 2026

What Atrial Fibrillation Is: Definition and Classification

Atrial fibrillation (AF or AFib) is an abnormal heart rhythm in which the two upper chambers of the heart—the atria—beat rapidly and irregularly instead of contracting in a coordinated, controlled manner. Rather than producing a steady pulse, the heart may beat anywhere from 100 to 300 times per minute, and the rhythm itself is chaotic and unpredictable.

AF is classified as a supraventricular tachycardia, meaning the abnormal rhythm originates above the ventricles (the heart's main pumping chambers). It is the most common serious cardiac arrhythmia globally, affecting over 33 million people as of 2020. Prevalence increases dramatically with age: fewer than 0.1% of people under 50 are affected, compared to 4% of those aged 60–70 and 14% of those over 80.

AF often begins as brief episodes of irregular beating and may progress to longer periods or become persistent. It can also develop from other arrhythmias, such as atrial flutter, that transform into AF over time.

How Atrial Fibrillation Works: The Electrical Mechanism

Normal Heart Rhythm vs. Atrial Fibrillation

Under normal conditions, a specialized cluster of cells called the sinoatrial (SA) node acts as the heart's natural pacemaker, generating electrical signals that spread in an orderly fashion through the atria, causing them to contract and push blood into the ventricles. This coordinated contraction is essential for efficient blood flow.

In atrial fibrillation, this organized electrical system breaks down. Instead of a single, orderly signal, multiple electrical impulses fire chaotically throughout the atrial muscle. This causes the atria to quiver or fibrillate rather than contract effectively.

Where AF Originates

Research has identified several common sources of these abnormal electrical signals:

• Pulmonary vein muscle bundles: Bursts of rapid activity often originate in muscle tissue extending from the atrium into the pulmonary veins—the vessels that return blood from the lungs. This is the most common source and a primary target for ablation therapy.
• Ganglionated plexi: Clusters of autonomic nerve tissue in the atrial wall can trigger erratic firing.
• Left atrial appendage and ligament of Marshall: These anatomical structures can also become sources of abnormal rhythm.
• General left atrial tissue: As AF becomes more persistent, the left atrium itself may develop independent arrhythmic activity.

Consequences for Blood Flow

Because the atria are not contracting forcefully or in sync, blood does not empty completely from them. This stagnant blood can pool and form clots, particularly in the left atrial appendage. These clots can travel to the brain and cause stroke—one of the most serious complications of untreated AF.

What the Research Shows: Evidence on Atrial Fibrillation Risk and Treatment

Prevalence and Epidemiology

As of 2014, AF affected 2–3% of the population in Europe and North America. The incidence is rising globally, driven largely by aging populations and increasing rates of underlying cardiac and metabolic disease. In developing regions, prevalence is lower (approximately 0.6% in males and 0.4% in females), but rates are climbing.

Risk Factors: Strong Evidence

Extensive research has identified the most modifiable and non-modifiable risk factors:

• High blood pressure: The single most common modifiable risk factor. Hypertension management significantly reduces AF incidence.
• Valvular heart disease: Abnormal heart valves disrupt normal blood flow patterns and electrical function. In low- and middle-income countries, rheumatic fever is a leading cause.
• Heart failure, coronary artery disease, cardiomyopathy: Structural heart disease alters the electrical substrate and increases AF risk.
• Lung disease: COPD, obesity, and obstructive sleep apnea are independently associated with AF.
• Lifestyle factors: Excess alcohol intake and tobacco smoking increase risk significantly.
• Metabolic factors: Diabetes mellitus is a documented risk factor.
• Thyroid dysfunction: Both subclinical hypothyroidism and thyrotoxicosis (overactive thyroid) increase AF susceptibility.
• Stress: Elevated cortisol and emotional stress may trigger or worsen AF, though the mechanism is still being clarified.

Important finding: Approximately 50% of AF cases occur without any of these identifiable risk factors, indicating AF can develop in relatively healthy individuals.

Stroke Risk: Grade A Evidence

AF increases stroke risk 5-fold compared to the general population. This is why anticoagulation (blood-thinning therapy) is central to AF management for most patients. Anticoagulants—including warfarin and direct oral anticoagulants (DOACs)—reduce stroke risk by approximately 64–66% in high-risk patients, though they do increase the risk of major bleeding.

Treatment Efficacy

Rate control vs. rhythm control: Clinical trials show that in hemodynamically stable patients, both strategies (slowing the heart rate vs. restoring normal rhythm) produce similar long-term outcomes. Choice depends on individual symptoms and circumstances.

Ablation: Catheter ablation, particularly pulmonary vein isolation, can restore normal sinus rhythm and reduce AF recurrence in selected patients. Success rates vary (50–80% depending on AF type and technique), but it remains an important option for rhythm control.

Lifestyle modification: Weight loss in obese patients, increased physical activity, and alcohol reduction have demonstrated evidence of reducing AF burden and incidence.

Symptoms of Atrial Fibrillation: What to Watch For

Many people with AF experience no symptoms at all and discover the condition only during routine examination or after a stroke. When symptoms do occur, they include:

• Heart palpitations: Sensation of rapid, irregular, or skipped heartbeats
• Shortness of breath: Due to inefficient blood pumping and resulting congestion
• Fatigue and weakness: From reduced cardiac output
• Dizziness or lightheadedness: Caused by inadequate blood flow to the brain
• Chest discomfort: Not classic angina, but pressure or heaviness
• Fainting or loss of consciousness: In severe cases with very rapid ventricular rates

Importantly, the absence of symptoms does not mean AF is safe. Stroke and heart failure can develop silently in asymptomatic patients, making regular cardiac screening important for those at risk.

Who Should Be Concerned: Risk Groups and Screening

Higher-Risk Populations

• Adults over age 60, particularly those over 75
• Anyone with a history of high blood pressure, heart disease, or diabetes
• Patients with chronic lung disease (COPD) or sleep apnea
• Those with a family history of AF
• Individuals with heavy alcohol use or active smoking
• People with obesity or metabolic syndrome

Screening and Diagnosis

AF is confirmed by electrocardiogram (ECG), which shows irregularly spaced heartbeats without organized P waves (the electrical signal for atrial contraction). A healthcare provider may suspect AF based on an irregular pulse during physical examination. Additional testing may include echocardiography (ultrasound of the heart) to assess structure and function.

Treatment Options for Atrial Fibrillation

Anticoagulation (Blood Thinners)

For most patients with AF, anticoagulation is the foundation of therapy. Options include:

• Warfarin (Coumadin): Traditional anticoagulant requiring regular monitoring; effective but requires dietary consistency
• Direct oral anticoagulants (DOACs): Newer agents (apixaban, dabigatran, edoxaban, rivaroxaban) with less monitoring required

These medications are recommended for all patients with AF at intermediate to high stroke risk. Patients at very low risk may not require anticoagulation, but this determination requires physician assessment using validated scoring tools.

Rate Control

Medications that slow the ventricular rate include beta-blockers, calcium channel blockers, and digoxin. The goal is usually a resting heart rate of 60–100 bpm, though some evidence supports a more lenient approach (up to 110 bpm) in stable patients.

Rhythm Control

Antiarrhythmic medications (such as flecainide, sotalol, amiodarone) aim to restore and maintain normal sinus rhythm. Success varies, and these drugs carry their own side effects and monitoring requirements.

Electrical Cardioversion

In acute or unstable AF, synchronized electrical shock can instantly restore normal rhythm. This is often the emergency treatment of choice for hemodynamically compromised patients.

Ablation

Catheter ablation, especially pulmonary vein isolation, is a catheter-based procedure that uses radiofrequency energy or cryotherapy to scar arrhythmogenic tissue. It is increasingly used as a first-line rhythm-control strategy in selected patients and can significantly reduce recurrence risk.

Safety Considerations and Drug Interactions

Anticoagulation Risks

The primary side effect of all anticoagulants is increased bleeding risk. Major bleeding occurs in approximately 2–3% of patients annually on warfarin, and slightly lower rates with DOACs. Regular monitoring and patient education on signs of bleeding (unusual bruising, blood in urine, black stools, severe headache) are essential.

Antiarrhythmic Drug Interactions

Antiarrhythmic medications can interact with numerous drugs and require careful dosing. Some increase bleeding risk when combined with anticoagulants. Others can cause proarrhythmia (paradoxically worsening arrhythmias) and require baseline and periodic ECG monitoring.